A solid-phase enzyme immunoassay (EIA) with the capture antibody principle was developed and evaluated for detection of immunoglobulin M (IgM) specific for group B coxsackieviruses (CBV) The group B coxsackieviruses (CBV) cause a wide spectrum of disease in humans, with the more serious infections involving the central nervous system and the heart (5, 9). Diagnosis of a CBV infection depends on virus isolation or serodiagnosis. However, diagnosis by virus culture is often difficult since the viremia and excretion of CBV often cease soon after the onset of symptoms (2). The neutralization test is the standard for serodiagnosis, but it is laborious and time consuming and requires paired sera.
The group B coxsackieviruses (CBV) cause a wide spectrum of disease in humans, with the more serious infections involving the central nervous system and the heart (5, 9). Diagnosis of a CBV infection depends on virus isolation or serodiagnosis. However, diagnosis by virus culture is often difficult since the viremia and excretion of CBV often cease soon after the onset of symptoms (2) . The neutralization test is the standard for serodiagnosis, but it is laborious and time consuming and requires paired sera.
The demonstration by Schmidt et al. (13) that early serum specimens contain immunoglobulin M (IgM) antibodies which precipitate complete CBV showed the potential diagnostic significance of CBV IgM as an indicator of a current or recent infection. El-Hagrassy et al. (4) , Dorries and ter Meulen (3), and Banatvala et al. (1) recently reported on serodiagnosis of CBV infections by an enzyme immunoassay (EIA) for IgM. The topic of diagnostic tests for CBV IgM recently was reviewed by Pattison (12) .
In our study, an EIA with the capture antibody principle was developed for the detection of CBV serotype-specific and pooled CBV-reactive IgM in human sera. The CBV IGM EIA results were similar to those of virus culture in terms of sensitivity and greatly superior to those of the microneutralization test. Our results support the serodiagnostic potential of CBV IgM detection by EIA. MATERIALS Microneutralization test. Sera from the 24 children in the CBV 4 outbreak were assayed for CBV-specific neutralizing antibodies by a microneutralization test. The sera were also fractionated on sucrose density gradients (11) , and after an overnight dialysis against phosphate-buffered saline (PBS), the IgM fractions were pooled and concentrated to the original volume in an Amicon S125 concentrator (Amicon Corp., Lexington, Mass.). These IgM fractions then were tested for antibodies to CBV by the microneutralization test. The initial serum dilutions of the IgM fractions were 1:1.25, which yielded an initial serum dilution of 1:2.5 in the IgM microneutralization test. Serial twofold dilutions were performed to a final dilution of 1:320.
EIA. Polystyrene beads (Precision Plastic Ball Co., Chicago, Ill.) were coated overnight at 4°C with affinity-purified goat anti-human IgM (Cappel Laboratories, Cochranville, Pa.) at 2 jig/ml in 0.06 M carbonate-bicarbonate buffer (pH 9.6). The beads were then postcoated with 1% bovine serum albumin in PBS (pH 7.3) for 1 h at room temperature. Coated beads were placed in 20-well polystyrene reaction trays (Abbott Laboratories, North Chicago, Ill.) and washed once with PBS containing 0.05% Tween 20 with an Abbott Pentawash. Patient serum was diluted 1:100 in PBS containing 2% bovine serum albumin and 0.15% Tween 20, and 0.2 ml of the diluted serum was added in duplicate to the virus antigen and control antigen wells. The reaction trays were then incubated at 37°C for 1 h and then washed five times with PBS-0.05% Tween 20. For the type-specific EIA, each CBV antigen (types 2 to 5) was adjusted to 50 jigI0.2 ml with PBS, and 0.2 ml of a single serotype was added to the appropriate wells. The pooled EIA used CBV 2 to 5 antigens adjusted to a total of 50 ,ug/0.2 ml before addition to the wells. (Viruses were not titered for these experiments. The approximate virus titers [50% tissue culture infective dose/0.025 RI] of similar preparations for CBV 2 to 5 were, respectively, 16510525, 675, and 17 A 0.2-ml amount of mock-infected cell supernatant fluid was added to the control antigen wells. Antigen was incubated with the beads for either 1 h at 37°C or overnight at 4°C and then washed five times with PBS-005% Tween 20. CBV 2 and 5 antisera diluted in PBS-2% bovine serum albumin-0.15% Tween 20
to an optimal concentration of 25 U/0.2 ml (1 U is the dilution of the neutralization endpoint titer) and CBV 3 and 4 antisera diluted to 5 U/0.2 ml were added to the appropriate wells in the type-specific assay and incubated at 37°C for 1 h. For the pooled assay, pooled CBV 2 to 5 antisera adjusted to a total concentration of 60 U/0.2 ml (in the same individual concentrations as in the serotype-specific assay above) were used. After this incubation, the beads were washed five times with PBS-0.05% Tween 20. A 0.2-ml amount of a peroxidase-conjugated F(ab)2 fragment goat anti-horse IgG (Cappel Laboratories) diluted 1:6,000 in PBS-2% bovine serum albumin-0.15% Tween 20 was added to the wells and incubated for 1 h at 37°C. Beads were then washed five times and transferred to new plates before the addition of substrate. The substrate solution, made immediately before use, consisted of 40 mg of o-phenylenediamine and 0.040 ml of 30% H202 in 100 ml of 0.01 M citrate-phosphate buffer (pH 5.0). A 0.4-ml amount of this solution was added to all wells and allowed to react for 30 min at 37°C.
The enzyme reaction was then terminated by the addition of 0.1 ml of 8 N H2SO4. The color reaction was quantitated by optical density (OD) at 492 nm in a Gilford Stasar III spectrophotometer (Gilford Instrument Laboratories, Inc., Oberlin, Ohio).
The serum of each patient was utilized as its own control with duplicate wells containing virus antigen and duplicate wells containing control antigen. The OD readings of the EIA tests were calculated as follows. The mean net OD equals the mean OD of virus antigen wells minus the mean OD of the control antigen wells. The negative cutoff value for the enzyme-linked immunosorbent assay was established by testing the cord bloods from 42 newborn infants known to be seronegative (titer of <1:10 by the microneutralization test) for antibody to CBV 2, 3, 4, and 5 (6). The cutoff OD was determined as the mean net OD plus 3 standard deviations of the EIA of the sera of newborns. The cutoff OD at a 1:100 dilution of serum for the serotype-specific tests was 0.080 and for the pooled antigen test was 0.105. Controls included a positive and negative serum control, an antiserum control (bead plus antiserum and conjugate), a conjugate control (bead plus conjugate), and a substrate control (bead plus substrate) which served as the blank for the spectrophotometer readings.
The reproducibility of the CBV pooled EIA was tested. For within-run variation, two sera were tested 20 times on the same day. For the interassay variation, 10 sera were tested on four separate days.
RESULTS
The results of the microneutralization tests, sucrose density gradient fractionation with microneutralization tests, and serotype-specific and pooled CBV EIA tests are illustrated ( 
